ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

UBT251

A development code. Also written as “UBT251 Injection 4.0 mg”, “UBT251 Injection 6.0 mg” and “UBT251 Injection 2.0 mg”.

In Novo Nordisk’s own words, UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon. Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Sleep Apnea, Obstructive · Fatty Liver, led by 2 companies.

Drug pageUBT251: every studyAll 12 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 9, 202612 company-led studies, 12 open or runningLicense: The United Laboratories → Novo Nordisk, Mar 2025Next primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
The United Laboratories Internationalits history only88 open or runningphase 3since Jun 9, 2026Aug 13, 2025Dec 2026phase 1 · NCT07785934
Novo Nordisk44 open or runningphase 2since Feb 1, 2026Feb 1, 2026Jan 14, 2027phase 2 · NCT07395687
  • Named in Novo Nordisk’s own pipeline as UBT251 (GLP-1/GIP/glucagon tri-agonist), phase 2, as of Nov 5, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2025Novo Nordisk licensed it from The United LaboratoriesLicenseEverywhere outside mainland China, Hong Kong, Macau and Taiwan · announced · The United Laboratories and Novo Nordisk (release)
  2. Feb 1, 2026First study: phase 2 study in OverweightFirst studyNCT07395687 · 333 planned · United States, Canada
  3. Jun 19, 2026Phase 2 study in Diabetes Mellitus, Type 2NCT07668388 · 300 planned · United States, Australia, Germany and more
  4. Jul 13, 20262 phase 1 studiesNCT07710768, NCT07710729

Ahead

  1. Jan 14, 2027Primary completion: phase 2 study in OverweightNCT07395687
  2. Apr 7, 2027Primary completion: phase 1 study in ObesityNCT07710768
  3. Apr 27, 2027Primary completion: phase 1 study in OverweightNCT07710729
  4. Oct 4, 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 2NCT07668388

TargetBeta

“UBT251, a triple agonist of the receptors for GLP-1, GIP and glucagon”company filing, read by Claude · source

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
retatrutideruleEli Lillyphase 333
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 4 Novo Nordisk leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710768Obesity · United States1RecruitingApr 7, 202744
NCT07710729Overweight · Canada1RecruitingApr 27, 202740
NCT07668388Diabetes Mellitus, Type 2 · United States, Australia, Germany and more2RecruitingOct 4, 2027300
NCT07395687Overweight · United States, Canada2RecruitingJan 14, 2027333

How it is read

Names in the registry

  • “UBT251”, 13 entries
  • “UBT251 Injection 4.0 mg”, 2 entries
  • “UBT251 Injection 6.0 mg”, 2 entries
  • “UBT251 Injection 2.0 mg”, 1 entry
  • “UBT251 Injection 2.0 mg group”, 1 entry

Codes read as this program: UBT251.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.